nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2A—Paclitaxel—Docetaxel—melanoma	0.0197	1	CbGdCrCtD
Dexrazoxane—TOP2B—hair follicle—melanoma	0.0128	0.302	CbGeAlD
Dexrazoxane—TOP2B—eye—melanoma	0.00637	0.151	CbGeAlD
Dexrazoxane—TOP2B—retina—melanoma	0.00631	0.15	CbGeAlD
Dexrazoxane—TOP2B—mammalian vulva—melanoma	0.00505	0.12	CbGeAlD
Dexrazoxane—Mediastinal disorder—Vemurafenib—melanoma	0.00489	0.00538	CcSEcCtD
Dexrazoxane—Phlebitis—Carmustine—melanoma	0.00481	0.0053	CcSEcCtD
Dexrazoxane—Alopecia—Vemurafenib—melanoma	0.00479	0.00528	CcSEcCtD
Dexrazoxane—Erythema—Vemurafenib—melanoma	0.00472	0.0052	CcSEcCtD
Dexrazoxane—Malnutrition—Vemurafenib—melanoma	0.00472	0.0052	CcSEcCtD
Dexrazoxane—Blood alkaline phosphatase increased—Temozolomide—melanoma	0.0046	0.00507	CcSEcCtD
Dexrazoxane—Extravasation—Docetaxel—melanoma	0.00421	0.00463	CcSEcCtD
Dexrazoxane—Hyponatraemia—Carmustine—melanoma	0.00416	0.00458	CcSEcCtD
Dexrazoxane—Cough—Vemurafenib—melanoma	0.00412	0.00454	CcSEcCtD
Dexrazoxane—Myalgia—Vemurafenib—melanoma	0.00402	0.00443	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00399	0.0044	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00399	0.00439	CcSEcCtD
Dexrazoxane—Pancytopenia—Bleomycin—melanoma	0.0039	0.00429	CcSEcCtD
Dexrazoxane—Blood bilirubin increased—Docetaxel—melanoma	0.00388	0.00427	CcSEcCtD
Dexrazoxane—Dysphagia—Dactinomycin—melanoma	0.00383	0.00422	CcSEcCtD
Dexrazoxane—Infection—Vemurafenib—melanoma	0.00383	0.00421	CcSEcCtD
Dexrazoxane—Nervous system disorder—Vemurafenib—melanoma	0.00378	0.00416	CcSEcCtD
Dexrazoxane—Skin disorder—Vemurafenib—melanoma	0.00374	0.00412	CcSEcCtD
Dexrazoxane—TOP2A—mammalian vulva—melanoma	0.00372	0.088	CbGeAlD
Dexrazoxane—Weight decreased—Bleomycin—melanoma	0.00371	0.00409	CcSEcCtD
Dexrazoxane—Pneumonia—Bleomycin—melanoma	0.00368	0.00405	CcSEcCtD
Dexrazoxane—Phosphatase alkaline increased—Docetaxel—melanoma	0.00367	0.00404	CcSEcCtD
Dexrazoxane—Injection site reaction—Docetaxel—melanoma	0.00365	0.00402	CcSEcCtD
Dexrazoxane—Pancytopenia—Dactinomycin—melanoma	0.00363	0.004	CcSEcCtD
Dexrazoxane—Breast disorder—Temozolomide—melanoma	0.00362	0.00399	CcSEcCtD
Dexrazoxane—TOP2B—head—melanoma	0.00362	0.0857	CbGeAlD
Dexrazoxane—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00361	0.00397	CcSEcCtD
Dexrazoxane—Dysphagia—Carmustine—melanoma	0.00358	0.00395	CcSEcCtD
Dexrazoxane—Neutropenia—Dactinomycin—melanoma	0.00358	0.00394	CcSEcCtD
Dexrazoxane—Stomatitis—Bleomycin—melanoma	0.00357	0.00393	CcSEcCtD
Dexrazoxane—Alanine aminotransferase increased—Temozolomide—melanoma	0.00353	0.00389	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00351	0.00387	CcSEcCtD
Dexrazoxane—Dysphagia—Temozolomide—melanoma	0.00346	0.00381	CcSEcCtD
Dexrazoxane—Pneumonia—Dactinomycin—melanoma	0.00343	0.00378	CcSEcCtD
Dexrazoxane—Pancytopenia—Carmustine—melanoma	0.0034	0.00375	CcSEcCtD
Dexrazoxane—Oesophagitis—Docetaxel—melanoma	0.00335	0.00369	CcSEcCtD
Dexrazoxane—Neutropenia—Carmustine—melanoma	0.00335	0.00369	CcSEcCtD
Dexrazoxane—Decreased appetite—Vemurafenib—melanoma	0.00335	0.00369	CcSEcCtD
Dexrazoxane—Stomatitis—Dactinomycin—melanoma	0.00333	0.00366	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Vemurafenib—melanoma	0.00333	0.00366	CcSEcCtD
Dexrazoxane—Fatigue—Vemurafenib—melanoma	0.00332	0.00366	CcSEcCtD
Dexrazoxane—Haemoglobin—Bleomycin—melanoma	0.0033	0.00364	CcSEcCtD
Dexrazoxane—Constipation—Vemurafenib—melanoma	0.00329	0.00363	CcSEcCtD
Dexrazoxane—Pancytopenia—Temozolomide—melanoma	0.00329	0.00362	CcSEcCtD
Dexrazoxane—Haemorrhage—Bleomycin—melanoma	0.00328	0.00362	CcSEcCtD
Dexrazoxane—Neutropenia—Temozolomide—melanoma	0.00324	0.00357	CcSEcCtD
Dexrazoxane—Pneumonia—Carmustine—melanoma	0.00321	0.00354	CcSEcCtD
Dexrazoxane—Depression—Carmustine—melanoma	0.00318	0.00351	CcSEcCtD
Dexrazoxane—Agranulocytosis—Dactinomycin—melanoma	0.00318	0.00351	CcSEcCtD
Dexrazoxane—Sepsis—Docetaxel—melanoma	0.00318	0.00351	CcSEcCtD
Dexrazoxane—Weight decreased—Temozolomide—melanoma	0.00313	0.00345	CcSEcCtD
Dexrazoxane—Stomatitis—Carmustine—melanoma	0.00311	0.00343	CcSEcCtD
Dexrazoxane—Pneumonia—Temozolomide—melanoma	0.0031	0.00342	CcSEcCtD
Dexrazoxane—Phlebitis—Docetaxel—melanoma	0.00309	0.00341	CcSEcCtD
Dexrazoxane—Infestation—Temozolomide—melanoma	0.00309	0.0034	CcSEcCtD
Dexrazoxane—Infestation NOS—Temozolomide—melanoma	0.00309	0.0034	CcSEcCtD
Dexrazoxane—Depression—Temozolomide—melanoma	0.00308	0.00339	CcSEcCtD
Dexrazoxane—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.00306	0.00337	CcSEcCtD
Dexrazoxane—Body temperature increased—Vemurafenib—melanoma	0.00304	0.00335	CcSEcCtD
Dexrazoxane—Stomatitis—Temozolomide—melanoma	0.00301	0.00331	CcSEcCtD
Dexrazoxane—Cardiac failure congestive—Docetaxel—melanoma	0.00294	0.00324	CcSEcCtD
Dexrazoxane—Alopecia—Bleomycin—melanoma	0.0029	0.0032	CcSEcCtD
Dexrazoxane—Haemoglobin—Carmustine—melanoma	0.00288	0.00317	CcSEcCtD
Dexrazoxane—Haemorrhage—Carmustine—melanoma	0.00287	0.00316	CcSEcCtD
Dexrazoxane—Erythema—Bleomycin—melanoma	0.00286	0.00315	CcSEcCtD
Dexrazoxane—Oedema peripheral—Carmustine—melanoma	0.00282	0.00311	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Carmustine—melanoma	0.00282	0.0031	CcSEcCtD
Dexrazoxane—Haemoglobin—Temozolomide—melanoma	0.00278	0.00307	CcSEcCtD
Dexrazoxane—Haemorrhage—Temozolomide—melanoma	0.00277	0.00305	CcSEcCtD
Dexrazoxane—Asthenia—Vemurafenib—melanoma	0.00276	0.00304	CcSEcCtD
Dexrazoxane—Oedema peripheral—Temozolomide—melanoma	0.00273	0.00301	CcSEcCtD
Dexrazoxane—Pruritus—Vemurafenib—melanoma	0.00272	0.003	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Temozolomide—melanoma	0.00272	0.003	CcSEcCtD
Dexrazoxane—Alopecia—Dactinomycin—melanoma	0.00271	0.00298	CcSEcCtD
Dexrazoxane—Hyponatraemia—Docetaxel—melanoma	0.00267	0.00295	CcSEcCtD
Dexrazoxane—Erythema—Dactinomycin—melanoma	0.00267	0.00294	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Bleomycin—melanoma	0.00265	0.00292	CcSEcCtD
Dexrazoxane—Anaemia—Bleomycin—melanoma	0.00264	0.00291	CcSEcCtD
Dexrazoxane—Diarrhoea—Vemurafenib—melanoma	0.00264	0.0029	CcSEcCtD
Dexrazoxane—Malaise—Bleomycin—melanoma	0.00258	0.00284	CcSEcCtD
Dexrazoxane—Cardiac disorder—Temozolomide—melanoma	0.00257	0.00283	CcSEcCtD
Dexrazoxane—Leukopenia—Bleomycin—melanoma	0.00256	0.00282	CcSEcCtD
Dexrazoxane—Dizziness—Vemurafenib—melanoma	0.00255	0.00281	CcSEcCtD
Dexrazoxane—Alopecia—Carmustine—melanoma	0.00253	0.00279	CcSEcCtD
Dexrazoxane—TOP2B—lymph node—melanoma	0.00253	0.06	CbGeAlD
Dexrazoxane—Angiopathy—Temozolomide—melanoma	0.00251	0.00277	CcSEcCtD
Dexrazoxane—Mental disorder—Carmustine—melanoma	0.00251	0.00277	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Temozolomide—melanoma	0.0025	0.00275	CcSEcCtD
Dexrazoxane—Erythema—Carmustine—melanoma	0.0025	0.00275	CcSEcCtD
Dexrazoxane—Malnutrition—Carmustine—melanoma	0.0025	0.00275	CcSEcCtD
Dexrazoxane—Cough—Bleomycin—melanoma	0.00249	0.00275	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Dactinomycin—melanoma	0.00247	0.00273	CcSEcCtD
Dexrazoxane—Anaemia—Dactinomycin—melanoma	0.00246	0.00271	CcSEcCtD
Dexrazoxane—Vomiting—Vemurafenib—melanoma	0.00245	0.0027	CcSEcCtD
Dexrazoxane—Alopecia—Temozolomide—melanoma	0.00245	0.0027	CcSEcCtD
Dexrazoxane—Myalgia—Bleomycin—melanoma	0.00243	0.00268	CcSEcCtD
Dexrazoxane—Mental disorder—Temozolomide—melanoma	0.00243	0.00267	CcSEcCtD
Dexrazoxane—Headache—Vemurafenib—melanoma	0.00241	0.00266	CcSEcCtD
Dexrazoxane—Malnutrition—Temozolomide—melanoma	0.00241	0.00266	CcSEcCtD
Dexrazoxane—Erythema—Temozolomide—melanoma	0.00241	0.00266	CcSEcCtD
Dexrazoxane—Breast disorder—Docetaxel—melanoma	0.00241	0.00265	CcSEcCtD
Dexrazoxane—Discomfort—Bleomycin—melanoma	0.0024	0.00265	CcSEcCtD
Dexrazoxane—Malaise—Dactinomycin—melanoma	0.0024	0.00265	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Docetaxel—melanoma	0.0024	0.00264	CcSEcCtD
Dexrazoxane—Leukopenia—Dactinomycin—melanoma	0.00239	0.00263	CcSEcCtD
Dexrazoxane—Alanine aminotransferase increased—Docetaxel—melanoma	0.00235	0.00259	CcSEcCtD
Dexrazoxane—Tremor—Carmustine—melanoma	0.00234	0.00258	CcSEcCtD
Dexrazoxane—Infection—Bleomycin—melanoma	0.00232	0.00255	CcSEcCtD
Dexrazoxane—Anaemia—Carmustine—melanoma	0.00231	0.00254	CcSEcCtD
Dexrazoxane—Dysphagia—Docetaxel—melanoma	0.0023	0.00254	CcSEcCtD
Dexrazoxane—Nausea—Vemurafenib—melanoma	0.00229	0.00252	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Bleomycin—melanoma	0.00228	0.00252	CcSEcCtD
Dexrazoxane—Myalgia—Dactinomycin—melanoma	0.00227	0.0025	CcSEcCtD
Dexrazoxane—Tremor—Temozolomide—melanoma	0.00226	0.00249	CcSEcCtD
Dexrazoxane—Discomfort—Dactinomycin—melanoma	0.00224	0.00247	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Temozolomide—melanoma	0.00224	0.00247	CcSEcCtD
Dexrazoxane—Leukopenia—Carmustine—melanoma	0.00223	0.00246	CcSEcCtD
Dexrazoxane—Anaemia—Temozolomide—melanoma	0.00223	0.00246	CcSEcCtD
Dexrazoxane—Anorexia—Bleomycin—melanoma	0.00222	0.00245	CcSEcCtD
Dexrazoxane—Pancytopenia—Docetaxel—melanoma	0.00219	0.00241	CcSEcCtD
Dexrazoxane—Malaise—Temozolomide—melanoma	0.00217	0.0024	CcSEcCtD
Dexrazoxane—Infection—Dactinomycin—melanoma	0.00216	0.00238	CcSEcCtD
Dexrazoxane—Leukopenia—Temozolomide—melanoma	0.00216	0.00238	CcSEcCtD
Dexrazoxane—Neutropenia—Docetaxel—melanoma	0.00215	0.00237	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Dactinomycin—melanoma	0.00213	0.00235	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Bleomycin—melanoma	0.00213	0.00234	CcSEcCtD
Dexrazoxane—Myalgia—Carmustine—melanoma	0.00212	0.00234	CcSEcCtD
Dexrazoxane—Cough—Temozolomide—melanoma	0.0021	0.00232	CcSEcCtD
Dexrazoxane—Weight decreased—Docetaxel—melanoma	0.00208	0.00229	CcSEcCtD
Dexrazoxane—Dyspnoea—Bleomycin—melanoma	0.00208	0.00229	CcSEcCtD
Dexrazoxane—Anorexia—Dactinomycin—melanoma	0.00207	0.00229	CcSEcCtD
Dexrazoxane—Pneumonia—Docetaxel—melanoma	0.00206	0.00227	CcSEcCtD
Dexrazoxane—Myalgia—Temozolomide—melanoma	0.00205	0.00226	CcSEcCtD
Dexrazoxane—Infestation NOS—Docetaxel—melanoma	0.00205	0.00226	CcSEcCtD
Dexrazoxane—Infestation—Docetaxel—melanoma	0.00205	0.00226	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00204	0.00225	CcSEcCtD
Dexrazoxane—Discomfort—Temozolomide—melanoma	0.00203	0.00223	CcSEcCtD
Dexrazoxane—Decreased appetite—Bleomycin—melanoma	0.00203	0.00223	CcSEcCtD
Dexrazoxane—Infection—Carmustine—melanoma	0.00202	0.00223	CcSEcCtD
Dexrazoxane—Dry mouth—Temozolomide—melanoma	0.00201	0.00221	CcSEcCtD
Dexrazoxane—Stomatitis—Docetaxel—melanoma	0.002	0.0022	CcSEcCtD
Dexrazoxane—Pain—Bleomycin—melanoma	0.002	0.0022	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Carmustine—melanoma	0.00199	0.0022	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00198	0.00218	CcSEcCtD
Dexrazoxane—Infection—Temozolomide—melanoma	0.00196	0.00215	CcSEcCtD
Dexrazoxane—Anorexia—Carmustine—melanoma	0.00194	0.00214	CcSEcCtD
Dexrazoxane—Nervous system disorder—Temozolomide—melanoma	0.00193	0.00213	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Temozolomide—melanoma	0.00193	0.00212	CcSEcCtD
Dexrazoxane—Feeling abnormal—Bleomycin—melanoma	0.00192	0.00212	CcSEcCtD
Dexrazoxane—Agranulocytosis—Docetaxel—melanoma	0.00192	0.00211	CcSEcCtD
Dexrazoxane—Skin disorder—Temozolomide—melanoma	0.00191	0.00211	CcSEcCtD
Dexrazoxane—Decreased appetite—Dactinomycin—melanoma	0.00189	0.00208	CcSEcCtD
Dexrazoxane—Fatigue—Dactinomycin—melanoma	0.00188	0.00207	CcSEcCtD
Dexrazoxane—Anorexia—Temozolomide—melanoma	0.00188	0.00207	CcSEcCtD
Dexrazoxane—TOP2A—lymph node—melanoma	0.00186	0.0441	CbGeAlD
Dexrazoxane—Pain—Dactinomycin—melanoma	0.00186	0.00205	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Carmustine—melanoma	0.00186	0.00204	CcSEcCtD
Dexrazoxane—Urticaria—Bleomycin—melanoma	0.00185	0.00204	CcSEcCtD
Dexrazoxane—Haemoglobin—Docetaxel—melanoma	0.00185	0.00204	CcSEcCtD
Dexrazoxane—Body temperature increased—Bleomycin—melanoma	0.00184	0.00203	CcSEcCtD
Dexrazoxane—Haemorrhage—Docetaxel—melanoma	0.00184	0.00203	CcSEcCtD
Dexrazoxane—Insomnia—Carmustine—melanoma	0.00184	0.00203	CcSEcCtD
Dexrazoxane—Dyspnoea—Carmustine—melanoma	0.00182	0.002	CcSEcCtD
Dexrazoxane—Oedema peripheral—Docetaxel—melanoma	0.00182	0.002	CcSEcCtD
Dexrazoxane—Somnolence—Carmustine—melanoma	0.00181	0.00199	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Docetaxel—melanoma	0.00181	0.00199	CcSEcCtD
Dexrazoxane—Feeling abnormal—Dactinomycin—melanoma	0.00179	0.00198	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Temozolomide—melanoma	0.00179	0.00198	CcSEcCtD
Dexrazoxane—Insomnia—Temozolomide—melanoma	0.00178	0.00196	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Dactinomycin—melanoma	0.00178	0.00196	CcSEcCtD
Dexrazoxane—Decreased appetite—Carmustine—melanoma	0.00177	0.00195	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Carmustine—melanoma	0.00176	0.00194	CcSEcCtD
Dexrazoxane—Dyspnoea—Temozolomide—melanoma	0.00175	0.00193	CcSEcCtD
Dexrazoxane—Somnolence—Temozolomide—melanoma	0.00175	0.00193	CcSEcCtD
Dexrazoxane—Pain—Carmustine—melanoma	0.00174	0.00192	CcSEcCtD
Dexrazoxane—Constipation—Carmustine—melanoma	0.00174	0.00192	CcSEcCtD
Dexrazoxane—Abdominal pain—Dactinomycin—melanoma	0.00172	0.0019	CcSEcCtD
Dexrazoxane—Body temperature increased—Dactinomycin—melanoma	0.00172	0.0019	CcSEcCtD
Dexrazoxane—Decreased appetite—Temozolomide—melanoma	0.00171	0.00188	CcSEcCtD
Dexrazoxane—Cardiac disorder—Docetaxel—melanoma	0.00171	0.00188	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Temozolomide—melanoma	0.0017	0.00187	CcSEcCtD
Dexrazoxane—Fatigue—Temozolomide—melanoma	0.0017	0.00187	CcSEcCtD
Dexrazoxane—Pain—Temozolomide—melanoma	0.00168	0.00185	CcSEcCtD
Dexrazoxane—Constipation—Temozolomide—melanoma	0.00168	0.00185	CcSEcCtD
Dexrazoxane—Feeling abnormal—Carmustine—melanoma	0.00168	0.00185	CcSEcCtD
Dexrazoxane—Asthenia—Bleomycin—melanoma	0.00167	0.00184	CcSEcCtD
Dexrazoxane—Angiopathy—Docetaxel—melanoma	0.00167	0.00184	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Carmustine—melanoma	0.00167	0.00183	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Docetaxel—melanoma	0.00166	0.00183	CcSEcCtD
Dexrazoxane—Pruritus—Bleomycin—melanoma	0.00165	0.00182	CcSEcCtD
Dexrazoxane—Alopecia—Docetaxel—melanoma	0.00163	0.00179	CcSEcCtD
Dexrazoxane—Feeling abnormal—Temozolomide—melanoma	0.00162	0.00179	CcSEcCtD
Dexrazoxane—Mental disorder—Docetaxel—melanoma	0.00161	0.00178	CcSEcCtD
Dexrazoxane—Body temperature increased—Carmustine—melanoma	0.00161	0.00177	CcSEcCtD
Dexrazoxane—Abdominal pain—Carmustine—melanoma	0.00161	0.00177	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Temozolomide—melanoma	0.00161	0.00177	CcSEcCtD
Dexrazoxane—Erythema—Docetaxel—melanoma	0.0016	0.00177	CcSEcCtD
Dexrazoxane—Malnutrition—Docetaxel—melanoma	0.0016	0.00177	CcSEcCtD
Dexrazoxane—Urticaria—Temozolomide—melanoma	0.00156	0.00172	CcSEcCtD
Dexrazoxane—Asthenia—Dactinomycin—melanoma	0.00156	0.00172	CcSEcCtD
Dexrazoxane—Abdominal pain—Temozolomide—melanoma	0.00156	0.00171	CcSEcCtD
Dexrazoxane—Body temperature increased—Temozolomide—melanoma	0.00156	0.00171	CcSEcCtD
Dexrazoxane—Diarrhoea—Dactinomycin—melanoma	0.00149	0.00164	CcSEcCtD
Dexrazoxane—Vomiting—Bleomycin—melanoma	0.00148	0.00163	CcSEcCtD
Dexrazoxane—Anaemia—Docetaxel—melanoma	0.00148	0.00163	CcSEcCtD
Dexrazoxane—Asthenia—Carmustine—melanoma	0.00146	0.00161	CcSEcCtD
Dexrazoxane—Syncope—Docetaxel—melanoma	0.00144	0.00158	CcSEcCtD
Dexrazoxane—Leukopenia—Docetaxel—melanoma	0.00144	0.00158	CcSEcCtD
Dexrazoxane—Asthenia—Temozolomide—melanoma	0.00141	0.00156	CcSEcCtD
Dexrazoxane—Loss of consciousness—Docetaxel—melanoma	0.00141	0.00155	CcSEcCtD
Dexrazoxane—Cough—Docetaxel—melanoma	0.0014	0.00154	CcSEcCtD
Dexrazoxane—Diarrhoea—Carmustine—melanoma	0.00139	0.00154	CcSEcCtD
Dexrazoxane—Pruritus—Temozolomide—melanoma	0.00139	0.00153	CcSEcCtD
Dexrazoxane—Nausea—Bleomycin—melanoma	0.00139	0.00153	CcSEcCtD
Dexrazoxane—Vomiting—Dactinomycin—melanoma	0.00138	0.00152	CcSEcCtD
Dexrazoxane—Myalgia—Docetaxel—melanoma	0.00137	0.0015	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00136	0.00149	CcSEcCtD
Dexrazoxane—Dizziness—Carmustine—melanoma	0.00135	0.00148	CcSEcCtD
Dexrazoxane—Diarrhoea—Temozolomide—melanoma	0.00135	0.00148	CcSEcCtD
Dexrazoxane—Dry mouth—Docetaxel—melanoma	0.00134	0.00147	CcSEcCtD
Dexrazoxane—Dizziness—Temozolomide—melanoma	0.0013	0.00143	CcSEcCtD
Dexrazoxane—Infection—Docetaxel—melanoma	0.0013	0.00143	CcSEcCtD
Dexrazoxane—Vomiting—Carmustine—melanoma	0.0013	0.00143	CcSEcCtD
Dexrazoxane—Nausea—Dactinomycin—melanoma	0.00129	0.00142	CcSEcCtD
Dexrazoxane—Shock—Docetaxel—melanoma	0.00129	0.00142	CcSEcCtD
Dexrazoxane—Nervous system disorder—Docetaxel—melanoma	0.00128	0.00141	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Docetaxel—melanoma	0.00128	0.00141	CcSEcCtD
Dexrazoxane—Headache—Carmustine—melanoma	0.00128	0.00141	CcSEcCtD
Dexrazoxane—Skin disorder—Docetaxel—melanoma	0.00127	0.0014	CcSEcCtD
Dexrazoxane—Vomiting—Temozolomide—melanoma	0.00125	0.00138	CcSEcCtD
Dexrazoxane—Anorexia—Docetaxel—melanoma	0.00125	0.00137	CcSEcCtD
Dexrazoxane—Headache—Temozolomide—melanoma	0.00123	0.00136	CcSEcCtD
Dexrazoxane—Nausea—Carmustine—melanoma	0.00121	0.00133	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Docetaxel—melanoma	0.00119	0.00131	CcSEcCtD
Dexrazoxane—Insomnia—Docetaxel—melanoma	0.00118	0.0013	CcSEcCtD
Dexrazoxane—Nausea—Temozolomide—melanoma	0.00117	0.00129	CcSEcCtD
Dexrazoxane—Dyspnoea—Docetaxel—melanoma	0.00117	0.00129	CcSEcCtD
Dexrazoxane—Somnolence—Docetaxel—melanoma	0.00116	0.00128	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—AURKA—melanoma	0.00115	0.038	CbGpPWpGaD
Dexrazoxane—Decreased appetite—Docetaxel—melanoma	0.00114	0.00125	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Docetaxel—melanoma	0.00113	0.00124	CcSEcCtD
Dexrazoxane—Fatigue—Docetaxel—melanoma	0.00113	0.00124	CcSEcCtD
Dexrazoxane—Pain—Docetaxel—melanoma	0.00112	0.00123	CcSEcCtD
Dexrazoxane—Constipation—Docetaxel—melanoma	0.00112	0.00123	CcSEcCtD
Dexrazoxane—Feeling abnormal—Docetaxel—melanoma	0.00108	0.00119	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Docetaxel—melanoma	0.00107	0.00118	CcSEcCtD
Dexrazoxane—Body temperature increased—Docetaxel—melanoma	0.00103	0.00114	CcSEcCtD
Dexrazoxane—Abdominal pain—Docetaxel—melanoma	0.00103	0.00114	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—RAI1—melanoma	0.000955	0.0315	CbGpPWpGaD
Dexrazoxane—Asthenia—Docetaxel—melanoma	0.000939	0.00103	CcSEcCtD
Dexrazoxane—Pruritus—Docetaxel—melanoma	0.000926	0.00102	CcSEcCtD
Dexrazoxane—Diarrhoea—Docetaxel—melanoma	0.000896	0.000987	CcSEcCtD
Dexrazoxane—TOP2A—G0 and Early G1—E2F1—melanoma	0.000895	0.0295	CbGpPWpGaD
Dexrazoxane—Dizziness—Docetaxel—melanoma	0.000866	0.000954	CcSEcCtD
Dexrazoxane—TOP2A—G0 and Early G1—PCNA—melanoma	0.000844	0.0279	CbGpPWpGaD
Dexrazoxane—Vomiting—Docetaxel—melanoma	0.000832	0.000917	CcSEcCtD
Dexrazoxane—Headache—Docetaxel—melanoma	0.00082	0.000903	CcSEcCtD
Dexrazoxane—Nausea—Docetaxel—melanoma	0.000778	0.000856	CcSEcCtD
Dexrazoxane—TOP2A—G0 and Early G1—CDK2—melanoma	0.000772	0.0255	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FASN—melanoma	0.000767	0.0253	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—PKMYT1—melanoma	0.000731	0.0241	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—NOTCH1—melanoma	0.000624	0.0206	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—APC—melanoma	0.00061	0.0201	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—melanoma	0.000574	0.0189	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—ARNT—melanoma	0.000568	0.0187	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PAX4—melanoma	0.000549	0.0181	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CAPN1—melanoma	0.000537	0.0177	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—SKP2—melanoma	0.000524	0.0173	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—melanoma	0.000442	0.0146	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—NODAL—melanoma	0.000433	0.0143	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—melanoma	0.000424	0.014	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—CTNNB1—melanoma	0.000393	0.013	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAP3K5—melanoma	0.000386	0.0127	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP10—melanoma	0.000386	0.0127	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—SKP2—melanoma	0.000368	0.0122	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—DCC—melanoma	0.000357	0.0118	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—APAF1—melanoma	0.000346	0.0114	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—melanoma	0.000337	0.0111	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—E2F1—melanoma	0.00033	0.0109	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—melanoma	0.000328	0.0108	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—melanoma	0.000327	0.0108	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—REC8—melanoma	0.000326	0.0108	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—MYC—melanoma	0.000318	0.0105	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—PCNA—melanoma	0.000311	0.0103	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—EGFR—melanoma	0.000311	0.0103	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK2—melanoma	0.000285	0.0094	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—melanoma	0.000269	0.00888	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—PKMYT1—melanoma	0.000268	0.00884	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—INCENP—melanoma	0.000268	0.00884	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—TP53—melanoma	0.000261	0.00862	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN2B—melanoma	0.000253	0.00835	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—GNA11—melanoma	0.000245	0.00809	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—INCENP—melanoma	0.00024	0.0079	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—PKMYT1—melanoma	0.00024	0.0079	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RB1—melanoma	0.000234	0.00772	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—E2F1—melanoma	0.000232	0.00766	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—HDAC2—melanoma	0.00023	0.0076	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—GNAQ—melanoma	0.000228	0.00752	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—PCNA—melanoma	0.000219	0.00723	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—NGFR—melanoma	0.00021	0.00694	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—POT1—melanoma	0.000202	0.00665	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK2—melanoma	0.0002	0.00661	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—melanoma	0.0002	0.00658	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—melanoma	0.000192	0.00633	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK4—melanoma	0.000189	0.00625	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—melanoma	0.000187	0.00618	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—melanoma	0.000182	0.00601	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FGF1—melanoma	0.00018	0.00593	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—E2F1—melanoma	0.000176	0.00581	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PDGFRA—melanoma	0.000174	0.00575	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—melanoma	0.000174	0.00573	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PRKCA—melanoma	0.000172	0.00569	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—melanoma	0.000169	0.00558	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—melanoma	0.000168	0.00555	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PCNA—melanoma	0.000166	0.00548	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RB1—melanoma	0.000165	0.00543	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—melanoma	0.000163	0.00538	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RAC1—melanoma	0.00016	0.00527	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—FAS—melanoma	0.000157	0.00516	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK2—melanoma	0.000152	0.00501	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN2A—melanoma	0.000145	0.00478	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—melanoma	0.000144	0.00475	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—melanoma	0.000143	0.00473	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MYC—melanoma	0.000139	0.0046	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CDK4—melanoma	0.000138	0.00454	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—SKP2—melanoma	0.000135	0.00446	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—APC—melanoma	0.000135	0.00446	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—NOS2—melanoma	0.000134	0.00442	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGF—melanoma	0.000134	0.0044	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1B—melanoma	0.000128	0.00423	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP8—melanoma	0.000126	0.00415	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PPARG—melanoma	0.000125	0.00413	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—melanoma	0.000124	0.00408	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—AURKA—melanoma	0.000124	0.00408	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND1—melanoma	0.000122	0.00403	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MLH1—melanoma	0.000122	0.00403	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—SKP2—melanoma	0.000121	0.00399	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	0.00012	0.00394	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1A—melanoma	0.000118	0.0039	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TP53—melanoma	0.000114	0.00378	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	0.000114	0.00375	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—AURKA—melanoma	0.00011	0.00365	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	0.000108	0.00356	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—APEX1—melanoma	0.000107	0.00354	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	0.000106	0.00351	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	0.000105	0.00346	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—melanoma	0.000103	0.00338	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYC—melanoma	9.81e-05	0.00324	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	9.71e-05	0.0032	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—APEX1—melanoma	9.6e-05	0.00317	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	9.52e-05	0.00314	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN2B—melanoma	9.28e-05	0.00306	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	9.27e-05	0.00306	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	9.18e-05	0.00303	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	8.96e-05	0.00296	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	8.94e-05	0.00295	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	8.9e-05	0.00294	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PTEN—melanoma	8.58e-05	0.00283	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—E2F1—melanoma	8.52e-05	0.00281	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—PRKCA—melanoma	8.35e-05	0.00275	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN2B—melanoma	8.3e-05	0.00274	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	8.08e-05	0.00266	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—PCNA—melanoma	8.04e-05	0.00265	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	7.64e-05	0.00252	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—E2F1—melanoma	7.62e-05	0.00251	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—PRKCA—melanoma	7.46e-05	0.00246	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—melanoma	7.43e-05	0.00245	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK2—melanoma	7.35e-05	0.00242	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	7.27e-05	0.0024	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	7.27e-05	0.0024	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—PCNA—melanoma	7.18e-05	0.00237	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK4—melanoma	6.95e-05	0.00229	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TERT—melanoma	6.94e-05	0.00229	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—melanoma	6.92e-05	0.00228	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	6.87e-05	0.00227	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDK2—melanoma	6.57e-05	0.00217	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	6.31e-05	0.00208	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—ATM—melanoma	6.24e-05	0.00206	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDK4—melanoma	6.21e-05	0.00205	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—melanoma	6.1e-05	0.00201	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RB1—melanoma	6.04e-05	0.00199	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TP53—melanoma	5.86e-05	0.00193	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RB1—melanoma	5.4e-05	0.00178	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—IL6—melanoma	5.36e-05	0.00177	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN2A—melanoma	5.31e-05	0.00175	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	5.15e-05	0.0017	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN2A—melanoma	4.75e-05	0.00157	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1B—melanoma	4.7e-05	0.00155	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MDM2—melanoma	4.6e-05	0.00152	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND1—melanoma	4.49e-05	0.00148	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1A—melanoma	4.34e-05	0.00143	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1B—melanoma	4.2e-05	0.00139	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND1—melanoma	4.01e-05	0.00132	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1A—melanoma	3.88e-05	0.00128	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MAPK3—melanoma	3.7e-05	0.00122	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYC—melanoma	3.6e-05	0.00119	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MAPK1—melanoma	3.52e-05	0.00116	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MAPK3—melanoma	3.31e-05	0.00109	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MYC—melanoma	3.22e-05	0.00106	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MAPK1—melanoma	3.15e-05	0.00104	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TP53—melanoma	2.64e-05	0.000872	CbGpPWpGaD
